<br />
HEPATOLOGY<br />
EMJ Hepatol. 2017 Suppl 5 • europeanmedical-journal.com<br />
INSIDE<br />
The Liver Meeting 2016<br />
THE LIVER MEETING 2016:<br />
Summary of presentations from the 67th Annual Liver Meeting<br />
of the American Association for the Study of Liver Diseases<br />
(AASLD), held in Boston, Massachusetts, USA,<br />
on 11th–15th November 2016<br />
Mia Cahill,1 *Chris Ontiveros2<br />
1. ApotheCom, London, UK<br />
2. ApotheCom, New York, USA<br />
*Correspondence to Chris.Ontiveros@apothecom.com<br />
Disclosure: This supplement has been funded by Gilead Sciences Europe Ltd. The content has been<br />
developed independently by the European Medical Journal, which has retained full editorial control. The<br />
views expressed do not necessarily reflect those of Gilead Sciences.<br />
Acknowledgements: Writing assistance was provided by Mia Cahill and<a title="EMJ Hepatol. 2017 Suppl 5 page 1" href="http://viewer.zmags.com/publication/d171b76a?page=1"> HEPATOLOGY EMJ Hepatol. 2017 Suppl 5 • europeanme</a>
<a title="EMJ Hepatol. 2017 Suppl 5 page 2" href="http://viewer.zmags.com/publication/d171b76a?page=2"> THE LIVER MEETING 2016: Summary of presentations </a>
<a title="EMJ Hepatol. 2017 Suppl 5 page 3" href="http://viewer.zmags.com/publication/d171b76a?page=3"> awareness of HBV results among high-ris</a>
<a title="EMJ Hepatol. 2017 Suppl 5 page 4" href="http://viewer.zmags.com/publication/d171b76a?page=4"> Table 1: Baseline characteristics of patients in </a>
<a title="EMJ Hepatol. 2017 Suppl 5 page 5" href="http://viewer.zmags.com/publication/d171b76a?page=5"> were more common versus HBcAg- hepatocytes (4.0 v</a>
<a title="EMJ Hepatol. 2017 Suppl 5 page 6" href="http://viewer.zmags.com/publication/d171b76a?page=6"> Table 2: Sequence changes observed through Week 4</a>
<a title="EMJ Hepatol. 2017 Suppl 5 page 7" href="http://viewer.zmags.com/publication/d171b76a?page=7"> are limited data on factors that affect AL</a>
<a title="EMJ Hepatol. 2017 Suppl 5 page 8" href="http://viewer.zmags.com/publication/d171b76a?page=8"> minimal decline in HBsAg. Patients with HBV</a>
<a title="EMJ Hepatol. 2017 Suppl 5 page 9" href="http://viewer.zmags.com/publication/d171b76a?page=9"> Of particular importance to chronic TDF therapy a</a>
<a title="EMJ Hepatol. 2017 Suppl 5 page 10" href="http://viewer.zmags.com/publication/d171b76a?page=10"> death from any cause, liver-related and unrelated</a>
<a title="EMJ Hepatol. 2017 Suppl 5 page 11" href="http://viewer.zmags.com/publication/d171b76a?page=11"> These results suggest that using peg-IFN-α with </a>
<a title="EMJ Hepatol. 2017 Suppl 5 page 12" href="http://viewer.zmags.com/publication/d171b76a?page=12"> hepatitis B virus infection. J Hepatol. 2012</a>